Pre-made Derlotuximab benchmark antibody ( Whole mAb Radiolabelled, anti-DNA;H1 Complex therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Derlotuximab benchmark antibody (Whole mAb Radiolabelled, anti-DNA;H1 Complex therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Iodine (131 I) derlotuximab biotin is a monoclonal antibody designed for the treatment of recurrent glioblastoma multiforme. This drug was developed by Peregrine Pharmaceuticals, Inc.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-143-1mg	1mg	Inquiry
GMP-Bios-ab-143-10mg	10mg	Inquiry
GMP-Bios-ab-143-100mg	100mg	Inquiry
GMP-Bios-ab-143-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Derlotuximab biosimilar, Whole mAb Radiolabelled: Anti-DNA/H1 Complex therapeutic antibody
INN Name	Derlotuximab
Target	DNA;H1 Complex
Format	Whole mAb Radiolabelled
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Avid Bioservices;MediPharm Biotech
Conditions Approved	Lung cancer
Conditions Active	Glioblastoma
Conditions Discontinued	na
Development Tech	na